COMMUNIQUÉS West-GlobeNewswire

-
Les données du système LithiX HC – IVL d’Elixir Medical démontrent une sécurité et une efficacité prolongées après six mois
30/10/2024 -
Comprehensive Healthcare launches “What we do means more” recruitment campaign highlighting rewarding careers in community behavioral health
30/10/2024 -
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
28/10/2024 -
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
28/10/2024 -
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
28/10/2024 -
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
28/10/2024 -
Certara to Participate in the Stephens Annual Investment Conference
28/10/2024 -
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
28/10/2024 -
Inari Medical Reports Third Quarter 2024 Financial Results
28/10/2024 -
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
28/10/2024 -
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
28/10/2024 -
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
28/10/2024 -
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
28/10/2024 -
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
28/10/2024 -
Sonablate announces first patient enrolled in HIFIVE U.S. clinical trial for ablation of incompetent veins
28/10/2024 -
Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
28/10/2024 -
Après six mois, le DynamX Bioadaptor d’Elixir Medical fait preuve d’une amélioration importante en comparaison des stents à élution médicamenteuse (DES), chez les patients atteints de syndrome coronarien aigu et de lésions complexes
28/10/2024 -
BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
28/10/2024 -
Oxford Treatment Center Leads the Way in Delivering Veteran Ready Care with New PsychArmor Certification
28/10/2024
Pages